PharmaTher Holdings has announced that it is building a portfolio of personalized, 3D-printed peptide products for the new U.S. compounding pathway, starting with oral, colon-targeted KPV and BPC-157. The company says the tablets are designed to carry the peptide past the stomach and release it in the colon.

The delivery technology comes from Singapore's Craft Health and is called CORR3CT: a 3D-printed pill-in-pill tablet with a drug-loaded core inside a pH-responsive shell. The shell is designed to resist stomach acid and delay release until the lower intestine, with extra printed layers used to tune where the dose lands.

Why the timing is now

The driver is an HHS enforcement discretion policy scheduled for publication in the Federal Register on October 30, 2026, creating a conditional pathway for qualified Section 503A pharmacies to compound six specified peptides. Those are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500, and of the six, only KPV and BPC-157 are covered for oral use.

That is a narrow door, and PharmaTher has walked straight through it. The policy sets conditions including peptide supply from an FDA-registered manufacturer, patient-specific prescribing, serious adverse-event reporting and documentation of adequate human oral bioavailability for an oral formulation.

What the data actually shows

The strongest number in the release is not about peptides at all. In a peer-reviewed 2023 in vitro study, CORR3CT tablets delivered up to 75 percent of their budesonide dose to a simulated colon, while the commercial comparator released more than 90 percent before reaching it.

On the peptides themselves, KPV has demonstrated anti-inflammatory activity in mouse colitis models, including a colon-targeted study reporting similar efficacy at a 12,000-fold lower concentration than free KPV. BPC-157 has limited early human ulcerative colitis experience using rectal administration, which is a long way from a printed oral tablet.

The gap the company is aiming at

The stated lead target is left-sided ulcerative colitis. PharmaTher cites figures that roughly 30 to 60 percent of ulcerative colitis patients have inflammation in the descending colon, which most oral budesonide products are not designed to reach.

Bottom line

Neither KPV nor BPC-157 is FDA-approved for any indication, and the company's own risk disclosures concede the clinical evidence is limited and largely preclinical. Compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before marketing, and whether in vitro colon targeting translates to humans remains the open question.